We're Developing Innovative Drugs for Metabolic Diseases
We are a dynamic biopharmaceutical company that uses our extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In our mid-to-late stage pipeline, we are currently advancing three drug candidates as well as earlier-stage opportunities from our AMPK activation and TZD platforms.
Leading Expertise in Metabolic Diseases
We were founded in 2009 through a spin-off of Merck Serono’s metabolic-focused business, as part of a strategic realignment following the acquisition of Serono by Merck, and assumed all key personnel in the diabetes group. Our management team is composed of experts with extensive experience in type 2 diabetes and related metabolic diseases. Key members of our team have experience from Merck Serono, Servier, Eli Lilly, and Merck and Co. and were involved in the discovery, clinical trial designs and regulatory approvals for a number of products prescribed globally, including Glucophage®, Trulicity®, Januvia® and others.
We have completed the Phase 3 development program for Imeglimin in Japan in partnership with Sumitomo Dainippon Pharma. We also completed the Phase 1 and 2 clinical development work in the United States and Europe. We continue to strengthen our management team, which now combines extensive experience in diabetes and metabolic disease clinical research and development and global regulatory affairs with the business and financial expertise needed for drug development and corporate partnerships.
As a result of our business development efforts, we secured our two pharmaceutical partnerships for Imeglimin leading to global rights, and we acquired PXL065, as well as additional programs, including deuterated drug candidates for all indications including metabolic, specialty and rare diseases.
We are continuing to build a world-class metabolic research and development organization with offices in Lyon, France, Boston, Massachusetts and Tokyo, Japan. In addition, our Board of Directors includes global experts in the pharmaceutical industry and our Scientific Advisory Board consists of leading diabetes and NASH experts.
Targeting Cellular Energy Regulation Pathways
We believe that targeting cellular energy regulation pathways for the treatment of metabolic diseases, including type 2 diabetes and NASH are of critical importance as disbalances are at the root of those diseases. All three of our clinical stage pipeline programs address significant targets in the energy metabolism pathways. Imeglimin targets mitochondrial dysfunction, mitochondria being the power station of the cell, PXL770 activates the adenosine monophosphate-activated protein kinase (AMPK), an important energy sensor, and PXL065 targets inhibition of the mitochondrial pyruvate carrier (MPC), the fuel gatekeeper.
Our goals are to develop and commercialize innovative therapies for the treatment of metabolic diseases, including type 2 diabetes and NASH as well as for chronic and rare-orphan metabolic disorders. To achieve these goals, we are pursuing the following strategies:
- Complete our worldwide clinical development and advance Imeglimin to commercialization together with our strategic partners, Sumitomo Dainippon Pharma for Japan, China and 11 East and Southeast Asian countries, for the treatment of type 2 diabetes.
- Advance PXL770 through clinical proof-of-concept development and enable progression into later-stage development for the treatment of NASH.
- Leverage the 505(b)(2) regulatory pathway to streamline the development program through Phase 3 for PXL065 for the treatment of NASH.
- Explore combination strategies for PXL770 and PXL065 for the treatment of NASH.
- Maximize the commercial potential of our wholly owned assets and opportunistically enter into strategic collaborations.
- Build on our metabolic disease franchise through expanding the portfolio by advancing our AMPK activation and TZD platforms, developing or acquiring additional drug candidates and technologies.
Backed by Years of Experience
Poxel was formed from the spin out of several metabolic drug candidates and a focused group of scientific and drug development leaders from Merck Serono.
Our scientific expertise is based on the understanding of key mechanisms involved in metabolic diseases and the innovation needed to make an impact on the current standard of care for these patients.
Our management team and Board of Directors have extensive pharmaceutical industry experience spanning the spectrum of drug research and development to commercialization, patient access and life-cycle management.
Interested in learning more about our programs and how we're combatting type 2 diabetes? Get in touch with us.